Literature DB >> 29755846

Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients.

Lotte Nygård1, Marianne C Aznar1, Barbara M Fischer2, Gitte F Persson1, Charlotte B Christensen2, Flemming L Andersen2, Mirjana Josipovic1,3, Seppo W Langer1, Andreas Kjær2, Ivan R Vogelius1, Søren M Bentzen4,5.   

Abstract

We measured the repeatability of FDG PET/CT uptake metrics when acquiring scans in free breathing (FB) conditions compared with deep inspiration breath hold (DIBH) for locally advanced lung cancer. Twenty patients were enrolled in this prospective study. Two FDG PET/CT scans per patient were conducted few days apart and in two breathing conditions (FB and DIBH). This resulted in four scans per patient. Up to four FDG PET avid lesions per patient were contoured. The following FDG metrics were measured in all lesions and in all four scans: Standardized uptake value (SUV)peak, SUVmax, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG), based on an isocontur of 50% of SUVmax. FDG PET avid volumes were delineated by a nuclear medicine physician. The gross tumor volumes (GTV) were contoured on the corresponding CT scans. Nineteen patients were available for analysis. Test-retest standard deviations of FDG uptake metrics in FB and DIBH were: SUVpeak FB/DIBH: 16.2%/16.5%; SUVmax: 18.2%/22.1%; SUVmean: 18.3%/22.1%; TLG: 32.4%/40.5%. DIBH compared to FB resulted in higher values with mean differences in SUVmax of 12.6%, SUVpeak 4.4% and SUVmean 11.9%. MTV, TLG and GTV were all significantly smaller on day 1 in DIBH compared to FB. However, the differences between metrics under FB and DIBH were in all cases smaller than 1 SD of the day to day repeatability. FDG acquisition in DIBH does not have a clinically relevant impact on the uptake metrics and does not improve the test-retest repeatability of FDG uptake metrics in lung cancer patients.

Entities:  

Keywords:  FB versus DIBH; FDG PET; lung cancer; repeatability

Year:  2018        PMID: 29755846      PMCID: PMC5944828     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  23 in total

1.  Monitoring ABC-assisted deep inspiration breath hold for left-sided breast radiotherapy with an optical tracking system.

Authors:  Kathryn E Mittauer; Rohan Deraniyagala; Jonathan G Li; Bo Lu; Chihray Liu; Sanjiv S Samant; Judith L Lightsey; Guanghua Yan
Journal:  Med Phys       Date:  2015-01       Impact factor: 4.071

2.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

3.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.

Authors:  Wouter van Elmpt; Dirk De Ruysscher; Anke van der Salm; Annemarie Lakeman; Judith van der Stoep; Daisy Emans; Eugène Damen; Michel Öllers; Jan-Jakob Sonke; José Belderbos
Journal:  Radiother Oncol       Date:  2012-04-06       Impact factor: 6.280

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer.

Authors:  Emmanuel Rios Velazquez; Chintan Parmar; Ying Liu; Thibaud P Coroller; Gisele Cruz; Olya Stringfield; Zhaoxiang Ye; Mike Makrigiorgos; Fiona Fennessy; Raymond H Mak; Robert Gillies; John Quackenbush; Hugo J W L Aerts
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

6.  Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability.

Authors:  Ralph T H Leijenaar; Sara Carvalho; Emmanuel Rios Velazquez; Wouter J C van Elmpt; Chintan Parmar; Otto S Hoekstra; Corneline J Hoekstra; Ronald Boellaard; André L A J Dekker; Robert J Gillies; Hugo J W L Aerts; Philippe Lambin
Journal:  Acta Oncol       Date:  2013-09-09       Impact factor: 4.089

7.  Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.

Authors:  Stephen S F Yip; John Kim; Thibaud P Coroller; Chintan Parmar; Emmanuel Rios Velazquez; Elizabeth Huynh; Raymond H Mak; Hugo J W L Aerts
Journal:  J Nucl Med       Date:  2016-09-29       Impact factor: 10.057

8.  Geometric uncertainties in voluntary deep inspiration breath hold radiotherapy for locally advanced lung cancer.

Authors:  Mirjana Josipovic; Gitte F Persson; Jenny Dueck; Jens Peter Bangsgaard; Gunnar Westman; Lena Specht; Marianne C Aznar
Journal:  Radiother Oncol       Date:  2015-11-26       Impact factor: 6.280

9.  Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients.

Authors:  Jochem W H Wolthaus; Jan-Jakob Sonke; Marcel van Herk; José S A Belderbos; Maddalena M G Rossi; Joos V Lebesque; Eugène M F Damen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-15       Impact factor: 7.038

Review 10.  Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.

Authors:  Feifei Na; Jingwen Wang; Cong Li; Lei Deng; Jianxin Xue; You Lu
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

View more
  2 in total

Review 1.  Challenges in the target volume definition of lung cancer radiotherapy.

Authors:  Susan Mercieca; José S A Belderbos; Marcel van Herk
Journal:  Transl Lung Cancer Res       Date:  2021-04

2.  Test-retest repeatability and interobserver variation of healthy tissue metabolism using 18F-FDG PET/CT of the thorax among lung cancer patients.

Authors:  Afnan A Malaih; Joel T Dunn; Lotte Nygård; David G Kovacs; Flemming L Andersen; Sally F Barrington; Barbara M Fischer
Journal:  Nucl Med Commun       Date:  2022-05-01       Impact factor: 1.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.